• Report Number: 180910906

Reports Overview

Pharmacovigilance Market: Overview

The increasing occurrence of adverse drug reaction (ADR) and the rising policies implemented by governments on drug safety regulations globally will fuel the growth of the global pharmacovigilance market. The market for pharmacovigilance has been growing in leaps and bounds owing to the increasing aging population, raising the introduction of new drugs. Furthermore, health regulatory authorities including EMEA and the U.S. FDA are pressurizing on submission of data through electronic mediums. This will also positively impact the growth of the global pharmacovigilance market.

This report presents quantitative information sets and elaborates upon the market dynamics such as the future prospects, drivers, and challenges. The competitive analysis tools such as attractive investment proposition have also been employed in order to present an accurate understanding of the overall market. The top regional segment driving the growth of the global pharmacovigilance market also forms a key part of this study.

In the competitive landscape section of the report, the main sustainability strategies implemented by the leading players and their impact on the development of the market have also been presented. The key market regulating factors have also been detailed under this study. Key monitoring tools such as SWOT analysis and Porter’s five forces analysis have also been utilized in order to provide a detailed understanding of the competition present in the overall pharmacovigilance market.

Pharmacovigilance Market: Drivers and Restraints

The increasing awareness amongst individuals on the safe utilization of medical interventions and medicines is amongst the key factors providing impetus to the development of the pharmacovigilance market. In addition, the rising count of national pharmacovigilance centers worldwide is positively impacting the growth of the overall market for pharmacovigilance. These centers are increasing awareness regarding safety of drugs amongst individuals, hence catapulting demand for pharmacovigilance.

On the other hand, the huge risk of data security and increasing perception on benefits or harmful effects of various drugs are amongst the key factors restraining the development of the market. In addition, the trend of web-based sales and drug information and the lack of skilled professionals may negatively impact the growth of the global pharmacovigilance market.

Pharmacovigilance Market: Region-wise Outlook

On the basis of geography, the global pharmacovigilance market is segmented into Europe, North America, Asia Pacific, and Rest of the World (RoW). Of these, the North America pharmacovigilance market held a significant share in the past owing to the rising mortality rate in this region because of increasing occurrence rate of ADRS and the growing concern on patients about the efficacy and safety of pharmaceutical products.

However, Asia Pacific is predicted to emerge as the most lucrative region in the market in the coming years. This is due to the rising demand for strict regulations on healthcare in Asia Pacific and the large pool of patients within this region. In addition, the growing need for effective pharmacovigilance services owing to the increasing count of clinical trials taking place in a number of Asia Pacific nations will also boost the development of the overall market.

Key players Mentioned in the Report are:

The top players in this market are Clinquest Group B.V., Accenture, Plc, Cognizant Technology Solutions, iMED Global Corporation, Covance, Inc. ICON, Plc, inVentiv Health, Inc., Pharmaceutical Product Development LLC, Parexel International Corporation, PRA Health Sciences, Inc., F. Hoffmann-La Roche Ltd., Quintiles Transnational Holdings Inc, Sanofi , Wipro Limited, and Synowledge LLC, among others.

Major regions analyzed under this research report are: 

  • North America
  • Asia Pacific
  • Europe
  • Rest of the World

This report gives you access to decisive data such as:

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years

Key highlights of this report:

  • Overview of key market forces propelling and restraining market growth
  • Up-to-date analyses of market trends and technological improvements
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors
  • An array of graphics and SWOT analysis of major industry segments
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis
  • Offers a clear understanding of the competitive landscape and key product segments

Table of Content

Chapter 1 Introduction
1.1 Report Description
1.2 Research Methodology
1.3 Market Segmentation
Chapter 2 Executive Summary
Chapter 3 Global Pharmacovigilance Market Dynamics
3.1 Introduction
3.2 Market Drivers
      3.2.1 Increasing Consumption of Drugs Would Fuel Demand for Continuous Drug Event Monitoring
      3.2.2 Rise in the Cases of Adverse Drug Reactions and Drug Toxicity Would Boost Demand for Pharmacovigilance Activities
      3.2.3 Rise in Adoption of Outsourcing Services Expected to Accentuate the Market Growth
3.3 Market Restraints
      3.3.1 High Risk Associated with Data Security in Pharmacovigilance Outsourcing
      3.3.2 Lack of Availability of Skilled Labor might Hinder the Market Growth
      3.3.3 Inadequate Pharmacovigilance System for Herbal Products in Asia Pacific Might Hamper the Market Growth
3.4 Market Opportunities
      3.4.1 Huge Scope for Rapid Growth of Pharmacovigilance Market in Emerging Economies
      3.4.2 Shift in Preference for Outsourcing among Various Pharmaceutical and Life Sciences Companies
3.5 Porter’s Five Forces Analysis: Global Pharmacovigilance Market
      3.5.1 Bargaining Power of Suppliers
      3.5.2 Bargaining Power of Buyers
      3.5.3 Threat of Substitutes
      3.5.4 Threat of New Entrants
      3.5.5 Competitive Rivalry
3.6 Market Attractiveness Analysis: Global Pharmacovigilance Market, by Geography
3.7 Competitive Landscape
      3.7.1 Market Share Analysis: Global Pharmacovigilance Market, 2013 (Value %)
Chapter 4 Global Pharmacovigilance Market, by Phases of Drug Development
4.1 Overview
      4.1.1 Global Pharmacovigilance Market Revenue, by Phases of Drug Development, 2012 – 2020 (USD Million)
      4.1.2 Comparative Analysis: Global Pharmacovigilance Market Revenue, by Type of Clinical Trial Phases, 2013 & 2020 (Value %)
4.2 Preclinical Studies
      4.2.1 Global Preclinical Studies Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
4.3 Phase I
      4.3.1 Global Phase I Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
4.4 Phase II
      4.4.1 Global Phase II Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
4.5 Phase III
      4.5.1 Global Phase III Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
4.6 Phase IV or Post Marketing Surveillance
      4.6.1 Global Phase IV Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
Chapter 5 Global Pharmacovigilance Market, By Type of Methods
5.1 Overview
      5.1.1 Global Pharmacovigilance Market Revenue, by Type of Methods , 2012 – 2020 (USD Million)
      5.1.2 Comparative Analysis: Global Pharmacovigilance Market Revenue, by Type of Methods, 2013 & 2020 (Value %)
5.3 Spontaneous Reporting
      5.3.1 Global Spontaneous Reporting Market Revenue, 2012 – 2020 (USD Million)
5.4 Intensified ADR Reporting
      5.4.1 Global Intensified ADR Reporting Market Revenue, 2012 – 2020 (USD Million)
5.5 Targeted Spontaneous Reporting
      5.5.1 Global Targeted Spontaneous Reporting Market Revenue, 2012 – 2020 (USD Million)
5.6 Cohort Event Monitoring
      5.6.1 Global Cohort Event Monitoring Market Revenue, 2012 – 2020 (USD Million)
5.7 EHR Mining
      5.7.1 Global EHR Mining Market Revenue, 2012 – 2020 (USD Million)
Chapter 6 Global Pharmacovigilance Market, by Type Service Providers
6.1 Overview
      6.1.1 Global Pharmacovigilance Market Revenue, by Type of Service Providers , 2012 – 2020 (USD Million)
      6.1.2 Comparative Analysis: Global Pharmacovigilance Market, by Type of Service Providers, 2013 & 2020 (Value %)
6.2 In-house Pharmacovigilance
      6.2.1 Global In-House Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
6.3 Contract Outsourcing
      6.3.1 Global Contract Outsourcing Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
Chapter 7 Global Pharmacovigilance Market, by Geography
7.1 Overview
      7.1.1 Global Pharmacovigilance Market Revenue, by Geography, 2012 – 2020 (USD Million)
7.2 North America
      7.2.1 North America Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
7.3 Europe
      7.3.1 Europe Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
7.4 Asia Pacific
      7.4.1 Asia Pacific Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
7.5 Rest of the World (RoW)
      7.5.1 RoW Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
Chapter 8 Recommendations
Chapter 9 Company Profiles
9.1 Accenture plc
      9.1.1 Company Overview
      9.1.2 Financial Overview
      9.1.3 Product Portfolio
      9.1.4 Business Strategies
      9.1.5 Recent Developments
9.2 Bristol-Myers Squibb
      9.2.1 Company Profile
      9.2.2 Financial Overview
      9.2.3 Product Portfolio
      9.2.4 Business Strategies
9.3 Clinquest Group B.V.
      9.3.1 Company Overview
      9.3.2 Financial Overview
      9.3.3 Product Portfolio
      9.3.4 Business Strategies
      9.3.5 Recent Developments
9.4 Cognizant Technology Solutions
      9.4.1 Company Overview
      9.4.2 Financial Overview
      9.4.3 Product Portfolio
      9.4.4 Business Strategies
      9.4.5 Recent Developments
9.5 Covance, Inc.
      9.5.1 Company Overview
      9.5.2 Financial Overview
      9.5.3 Product Portfolio
      9.5.4 Business Strategies
      9.5.5 Recent Developments
9.6 F. Hoffmann-La Roche Ltd.
      9.6.1 Company Overview
      9.6.2 Financial Overview
      9.6.3 Product Portfolio
      9.6.4 Business Strategies
      9.6.5 Recent Development
9.7 GlaxoSmithKline plc (GSK)
      9.7.1 Company Overview
      9.7.2 Financial Overview
      9.7.3 Product Portfolio
      9.7.4 Business Strategies
      9.7.5 Recent Developments
9.8 ICON plc
      9.8.1 Company Overview
      9.8.2 Financial Overview
      9.8.3 Product Portfolio
      9.8.4 Business Strategy
      9.8.5 Recent Developments
9.9 iGATE Corporation
      9.9.1 Company Overview
      9.9.2 FINANCIAL Overview
      9.9.3 Product Portfolio
      9.9.4 Business Strategies
      9.9.5 Recent Developments
9.10 iMEDGlobal Corporation
      9.10.1 Company Overview
      9.10.2 Financial Overview
      9.10.3 Product Portfolio
      9.10.4 Business Strategies
      9.10.5 Recent Developments
9.11 inVentiv Health, Inc.
      9.11.1 Company Overview
      9.11.2 Financial Overview
      9.11.3 Product Portfolio
      9.11.4 Business Strategies
      9.11.5 Recent Developments
9.12 Novartis International AG
      9.12.1 Company Overview
      9.12.2 Financial Overview
      9.12.3 Product Portfolio
      9.12.4 Business Strategies
      9.12.5 Recent Developments
9.13 PAREXEL International Corporation
      9.13.1 Company Overview
      9.13.2 Financial Overview
      9.13.3 Product Portfolio
      9.13.4 Recent Developments
9.14 Pfizer, Inc.
      9.14.1 Company Overview
      9.14.2 Financial Overview
      9.14.3 Product Portfolio
      9.14.4 Business Strategies
      9.14.5 Recent Developments
9.15 Pharmaceutical Product Development, LLC. (PPD)
      9.15.1 Company Overview
      9.15.2 Financial Overview
      9.15.3 Product Portfolio
      9.15.4 Business Strategies
      9.15.5 Recent Developments
9.16 PRA Health Sciences, Inc.
      9.16.1 Company Overview
      9.16.2 Financial Overview
      9.16.3 Product Portfolio
      9.16.4 Business Strategies
      9.16.5 Recent Developments
9.17 Quintiles Transnational Holdings, Inc.
      9.17.1 Company Overview
      9.17.2 Financial Overview
      9.17.3 Product Portfolio
      9.17.4 Business Strategies
      9.17.5 Recent Developments
9.18 Sanofi
      9.18.1 Company Overview
      9.18.2 Financial Overview
      9.18.3 Product Portfolio
      9.18.4 Business Strategies
      9.18.5 Recent Developments
9.19 Synowledge LLC
      9.19.1 Company Overview
      9.19.2 Financial Overview
      9.19.3 Product Portfolio
      9.19.4 Business Strategies
      9.19.5 Recent Developments
9.20 Wipro Limited
      9.20.1 Company Overview
      9.20.2 Financial Overview
      9.20.3 Product Portfolio
      9.20.4 Business Strategies

 

Analyst Review

With collective industry experience of about 200 years of its analysts and experts, Future Industry Insight (FII) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With FII’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
Future Industry Insight (FII) has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, FII’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

There are no reviews yet.

Be the first to review “Pharmacovigilance Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020”